• 尊时凯龙

    R&D Pipeline

    Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.

    Major Drugs under Development

    As of December 2023, Fosun Pharma has 70+ major innovative drugs and biosimilars under development (calculated by indication).

    • 20
      Self-developed small molecule innovator drug
    • 25
      Self-developed innovative biologics
    • 20
      In-licensing innovator drugs
    • 10
      Self-developed biosimilars